Subscribe
Share
Share
Embed
Italy hits €5.4B in supplements as Il Fatto Alimentare questions need; Food Dive warns GLP-1 labels mislead; Willie's Remedy+ bets on growth before US ban.
Italy just became Europe's biggest supplement market at €5.4B — and journalists are already questioning whether any of it is necessary. Plus: why slapping 'GLP-1 friendly' on your product could be your brand's next liability.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: There's a lot to get through today, so let's dive straight in.
Klara: Italy just became Europe's biggest supplement market — and journalists are already asking whether any of it is necessary.
Marco: We're also unpacking the 'GLP-1 friendly' label trend, which is moving faster than the science behind it.
Klara: Plus walnuts and gut health, and a hemp brand sprinting toward a US federal ban.
Marco: Let's get into it.
Marco: Italy is now the biggest supplement market in Europe — and that headline is coming with some uncomfortable questions attached.
Marco: The European supplement industry has been growing steadily for years. Consumers across the continent are spending more on vitamins, minerals, and functional products than ever before. Italy has quietly led that charge, and now the numbers make it official.
Marco: According to reporting from Il Fatto Alimentare, Italy's supplement market has hit €5.4 billion, putting it ahead of every other European country. That's a remarkable figure. But the same article is asking a pointed question — do Italians actually need what they're buying? The piece argues that advertising, not genuine nutritional deficiency, is what's driving much of this demand. It also highlights something that matters enormously to this industry: many consumers don't fully understand the difference between a supplement and a pharmaceutical. Supplements don't have to prove they work before going on sale. Drugs do.
Klara: That distinction is critical. Under EU law — specifically the food supplements directive — manufacturers don't need to demonstrate clinical efficacy before selling a product. They can only use health claims that EFSA, the European Food Safety Authority, has formally approved. But many brands operate right at the edge of those rules, using vague language that implies more than the evidence supports. Media scrutiny like this tends to accelerate regulatory attention.
Marco: Commercially, I'd frame this differently. A €5.4 billion market is proof that demand is real, whatever drives it. The brands that will struggle are the ones built entirely on hype. The ones investing in transparent labelling, authorised claims, and genuine consumer education — those are actually in a stronger position as this narrative grows.
Klara: The scrutiny is an opportunity, if brands are brave enough to treat it that way.
Marco: Now let's move to our next story.
Klara: Food companies are racing to stamp 'GLP-1 friendly' on their products — and nutrition experts are already raising the alarm.
Klara: GLP-1 drugs — medications like semaglutide that suppress appetite and are used for weight management — have created an enormous new consumer segment almost overnight. Brands naturally want a piece of that. But slapping a label on a product and actually serving that consumer's needs are very different things.
Klara: Food Dive reports that a growing number of food and supplement companies are launching products under the 'GLP-1 friendly' banner. The core problem, according to nutrition experts quoted in the piece, is that GLP-1 users are not one type of person. They have different health profiles, different dietary needs, different reasons for being on the medication. A label that treats them as a single group is, scientifically speaking, a fiction.
Klara: From a regulatory standpoint, this is a grey area with real teeth. There is no EFSA-authorised health claim — no formally approved scientific basis — for 'GLP-1 friendly' as a phrase. That means brands using it are operating without a regulatory safety net. If a national authority decides the label is misleading under EU food information rules, the exposure is significant.
Marco: Commercially, I understand the instinct. This is a fast-growing audience and brands want visibility. But 'GLP-1 friendly' as a pure positioning play, with nothing solid behind it, is a short-term bet. The brands I'd back are the ones actually engineering for this consumer — high protein, high fibre, dense micronutrients — and letting the formulation speak.
Klara: The label without the substance is just noise. And experts are already cutting through it.
Marco: Let's move to our next story.
Marco: German nutrition media is shining a light on California walnuts as a gut health ingredient — and it's worth paying attention to.
Marco: Gut microbiome research is one of the most commercially exciting spaces in European wellness right now. Consumers are actively looking for food and supplement solutions that support digestive health. The science is still maturing, but the category is already enormous.
Marco: Ernährungs Umschau — a respected German nutrition science publication — has highlighted research examining how walnut consumption affects the composition of the gut microbiome, meaning the trillions of bacteria living in the digestive tract. The California Walnut Commission is funding and actively promoting this research. That's a deliberate move to position walnuts as a whole-food, clean-label prebiotic source — a food that feeds beneficial gut bacteria — rather than just a healthy snack.
Klara: The science around walnuts and gut microbiome composition is genuinely interesting. Walnuts contain fibre, polyphenols, and alpha-linolenic acid — an omega-3 fatty acid — all of which may influence microbial diversity. But I want to be careful here. Much of the existing research is preliminary. We don't yet have EFSA-authorised health claims linking walnuts specifically to gut microbiome health. Marketers who want to run with this science need to stay within approved claim boundaries — that means sticking to claims like fibre supporting normal bowel function, not promising microbiome transformation.
Marco: I'd separate the regulatory caution from the commercial opportunity, though. A whole food with a credible science narrative, clean label credentials, and no pill format — that is a genuinely powerful story for functional food brands. The California Walnut Commission is essentially behaving like an ingredient brand now. Commodity bodies investing in clinical credibility — that's a structural shift worth watching.
Klara: The story is compelling. The claim just needs to stay honest.
Marco: That takes us to our final story for today.
Klara: A US hemp drinks brand is accelerating its growth strategy weeks before a potential federal ban — and European marketers should be watching closely.
Klara: The hemp and CBD wellness category has always operated in regulatory grey zones on both sides of the Atlantic. In the US, intoxicating hemp products have proliferated rapidly since hemp was federalised as a legal crop in 2018. But that window may be closing fast.
Klara: BevNet reports that Willie's Remedy+, a hemp wellness drink from JuneShine Brands, is pushing forward with distribution and brand-building despite a December 11 deadline for a potential federal prohibition on intoxicating hemp products. Rather than pausing to see how the law lands, the brand is accelerating. That is either a calculated bet or a significant miscalculation — possibly both.
Klara: From a regulatory standpoint, this is a cautionary tale. Building brand equity in a category where the legal foundation is genuinely unstable is a high-risk move. The EU's own CBD situation isn't dissimilar. Novel food authorisation for CBD — the formal approval process required before it can be legally sold as a food ingredient across the EU — has been crawling for years. Several applications are still pending. Brands that have invested heavily in CBD product lines are sitting on similar uncertainty here.
Marco: I actually think there's a defensible commercial logic to what Willie's Remedy+ is doing. If a ban does land, the brands with the strongest distribution footprint and consumer recognition will be best placed to pivot quickly — reformulating, repositioning, or lobbying for carve-outs. Standing still doesn't protect you either.
Klara: That logic holds up until it doesn't. Regulatory risk isn't the same as market risk. A prohibition can erase a category overnight, not just slow it down. Brand equity means very little if the product is off the shelf by law.
Marco: The honest takeaway for European brands is this: know exactly where your regulatory floor is before you build anything on top of it.
Marco: If today's stories have one commercial thread, it's this — labels are writing cheques that the science can't always cash.
Klara: And regulators, journalists, and consumers are increasingly reading the small print.
Marco: In this market, the brands built on substance will outlast the ones built on noise.